Cully Pharmaceutical-B (01672): ITC made a final ruling on the Viking lawsuit. The final ruling mainly included banning the import of ASC41 and ASC43F for a period of seven years

Zhitong Finance App News, Goli Pharmaceutical-B (01672) issued an announcement regarding the legal lawsuit involving the Group and Viking Therapeutics, Inc. (Viking, a pharmaceutical company based in the United States). The ITC made a final ruling (final judgment) on Viking's complaint on May 29, 2025 (EST). The final judgment mainly included a ban on the import of ASC41 and ASC43F for a period of seven years; and the Company and its former legal advisors jointly undertook to pay $5671 million as a penalty for procedural disputes arising from the case. Dr. Wu Jinzi, the founder of the Company, or any other assets of the Company have not been sanctioned.

Since the Company has previously announced that it will no longer promote ASC41 and ASC43F, the Company believes that it will not have any significant adverse impact on the Group, and the Group's current business and operations are continuing normally.

ASC41 is a self-developed oral tablet targeting thyroid hormone beta receptor (THRbeta) using our own technology to treat non-alcoholic steatohepatitis (NASH). ASC43F is a self-developed dual-target fixed-dose combination formulation (FDC) oral tablet using our own technology and targeting THRbeta and farnesol X receptor (FXR) for the treatment of NASH. The Group is currently seeking further legal advice on appeal against the final judgement (including monetary sanctions).

The Company will continue to make every effort to protect its trade secrets and will issue further announcements in due course regarding any significant developments in the Viking complaint or any other action the Company may take.